With no single headline event in play, Ingevity (NGVT) has still been drawing attention after a month that included an 8.7% return and a move of 37.9% over the past 3 months.
See our latest analysis for Ingevity.
That recent 8.7% 1 month share price return and 37.9% 3 month share price return sit alongside a 19.9% year to date share price gain. At the same time, the 1 year total shareholder return of 51.1% contrasts with slightly negative total shareholder returns over three and five years, suggesting improving momentum after a tougher stretch.
If Ingevity’s move has you thinking about where else capital could work hard, this is a good moment to broaden your search with our 8 top copper producer stocks as a starting list of ideas.
With shares around $72.03, a price target of $73.50 close by, and an intrinsic value estimate implying a 40.1% discount, is Ingevity still on sale, or is the market already pricing in future growth potential?
Most Popular Narrative: 1.8% Overvalued
With Ingevity at $72.03 and the most followed fair value estimate sitting at $70.75, the valuation gap is narrow, so the underlying story matters more than the headline number.
Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile. This is intended to enable greater focus and capital allocation toward higher-growth, value-added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement.
Read the complete narrative. Read the complete narrative.
Curious how a modest premium to fair value can still rest on ambitious margin shifts and future earnings power, all discounted at 8.37%? The narrative leans heavily on a reshaped portfolio, richer mix and a different profit profile to support that $70.75 figure. If you want to see how those moving parts fit together, the full breakdown makes the assumptions very clear.
Result: Fair Value of $70.75 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that story can quickly change if APT weakness, tariffs and industrial softness deepen or if portfolio sales fail to deliver the expected margin uplift.
Find out about the key risks to this Ingevity narrative.
Another View: Cash Flows Point to a Very Different Price
While the most followed fair value estimate sits at $70.75 and flags Ingevity as 1.8% overvalued, our DCF model presents a different perspective. On that view, the shares at $72.03 are trading at a 40.1% discount to an estimated future cash flow value of $120.31. So which story do you trust more: the earnings multiple or the cash flow math?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ingevity for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this mix of upside and risk has you on the fence, do not sit back and wait for clarity. Instead, weigh the trade off yourself with our 2 key rewards and 1 important warning sign.
Ready for more investment ideas?
If Ingevity has caught your eye, do not stop there. The market is full of opportunities, and a quick screener run could surface ideas you will not want to miss.
- Target value first by checking out our 46 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their underlying strength.
- Prioritise resilience with our 76 resilient stocks with low risk scores to focus on companies that score well on stability and risk metrics.
- Hunt for early standouts through a screener containing 24 high quality undiscovered gems that many investors may not be watching yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com